MX389310B - Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso. - Google Patents

Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.

Info

Publication number
MX389310B
MX389310B MX2017016801A MX2017016801A MX389310B MX 389310 B MX389310 B MX 389310B MX 2017016801 A MX2017016801 A MX 2017016801A MX 2017016801 A MX2017016801 A MX 2017016801A MX 389310 B MX389310 B MX 389310B
Authority
MX
Mexico
Prior art keywords
drospirenone
female patients
excess weight
patients affected
based contraceptives
Prior art date
Application number
MX2017016801A
Other languages
English (en)
Spanish (es)
Other versions
MX2017016801A (es
Inventor
Cécile Boyer-Joubert
Dominique Drouin
Philippe Perrin
Original Assignee
Laboratorios Leon Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56178376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX389310(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP15305965.4A external-priority patent/EP3108889A1/en
Priority claimed from CN201510348953.1A external-priority patent/CN106265694A/zh
Application filed by Laboratorios Leon Farma Sa filed Critical Laboratorios Leon Farma Sa
Publication of MX2017016801A publication Critical patent/MX2017016801A/es
Publication of MX389310B publication Critical patent/MX389310B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2017016801A 2015-06-23 2016-06-23 Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso. MX389310B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305965.4A EP3108889A1 (en) 2015-06-23 2015-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight
CN201510348953.1A CN106265694A (zh) 2015-06-23 2015-06-23 用于过重女性患者的基于屈螺酮的避孕药
PCT/EP2016/064574 WO2016207298A1 (en) 2015-06-23 2016-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight

Publications (2)

Publication Number Publication Date
MX2017016801A MX2017016801A (es) 2018-05-11
MX389310B true MX389310B (es) 2025-03-20

Family

ID=56178376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016801A MX389310B (es) 2015-06-23 2016-06-23 Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.

Country Status (26)

Country Link
EP (1) EP3313408B1 (enExample)
JP (1) JP6827962B2 (enExample)
KR (1) KR102217942B1 (enExample)
CN (2) CN113750108B (enExample)
AU (1) AU2016282863B2 (enExample)
BR (1) BR112017028048A2 (enExample)
CA (1) CA2989975C (enExample)
DK (1) DK3313408T3 (enExample)
EA (1) EA036497B1 (enExample)
ES (1) ES2970532T3 (enExample)
FI (1) FI3313408T3 (enExample)
HR (1) HRP20240121T8 (enExample)
HU (1) HUE065350T2 (enExample)
LT (1) LT3313408T (enExample)
MX (1) MX389310B (enExample)
MY (1) MY187233A (enExample)
NI (1) NI201700173A (enExample)
PH (1) PH12017502379A1 (enExample)
PL (1) PL3313408T3 (enExample)
RS (1) RS65196B1 (enExample)
SI (1) SI3313408T1 (enExample)
SM (1) SMT202400062T1 (enExample)
SV (1) SV2017005602A (enExample)
UA (1) UA122873C2 (enExample)
WO (1) WO2016207298A1 (enExample)
ZA (1) ZA201800067B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
JP6827962B2 (ja) 2015-06-23 2021-02-10 ラボラトリオス レオン ファーマ エスエー 過剰体重に影響される女性患者のためのドロスピレノン系避妊薬
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
EP3781171B1 (en) 2018-04-19 2022-02-09 Estetra SRL Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GT200500099A (es) * 2004-04-30 2006-05-05 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
AR049707A1 (es) * 2004-07-07 2006-08-30 Wyeth Corp Regimenes y kits de progestina ciclica
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
ES2311927T5 (es) 2005-07-21 2014-09-08 Bayer Pharma Aktiengesellschaft Proceso para la producción de 3-oxo-pregn-4-en-21,17-carbolactonas por la oxidación sin metales de 17-(3-hidroxipropil)-3,17-dihidroxiandrostanos
UY31010A1 (es) * 2007-04-05 2008-11-28 Bayer Schering Pharma Ag Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion
CN102395596B (zh) * 2010-03-16 2013-02-13 台州太法药业有限公司 屈螺酮制备方法
RU2422824C1 (ru) * 2010-05-07 2011-06-27 Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи Способ выбора тактики лечения нарушений менструального цикла у девочек-подростков с избыточной массой тела
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
AR081670A1 (es) * 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CN103372015A (zh) * 2012-04-19 2013-10-30 国家人口计生委科学技术研究所 包含屈螺酮或屈螺酮和雌激素的阴道环制剂
RU2527357C1 (ru) * 2013-08-02 2014-08-27 Государственное бюджетное образовательное Учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации (МГМСУ имени А.И. Евдокимова" Минздрава России) Способ персонифицированной профилактики эстрогензависимых заболеваний у здоровых женщин и женщин с факторами сердечно-сосудистого риска в возрасте 45-60 лет
JP6827962B2 (ja) 2015-06-23 2021-02-10 ラボラトリオス レオン ファーマ エスエー 過剰体重に影響される女性患者のためのドロスピレノン系避妊薬

Also Published As

Publication number Publication date
HUE065350T2 (hu) 2024-05-28
HRP20240121T1 (hr) 2024-04-12
HRP20240121T8 (hr) 2024-05-10
WO2016207298A1 (en) 2016-12-29
JP6827962B2 (ja) 2021-02-10
AU2016282863A1 (en) 2018-02-08
MY187233A (en) 2021-09-13
FI3313408T3 (fi) 2024-01-25
RS65196B1 (sr) 2024-03-29
HK1255216A1 (zh) 2019-08-09
CN113750108A (zh) 2021-12-07
PL3313408T3 (pl) 2024-04-15
CN108025014B (zh) 2021-10-22
UA122873C2 (uk) 2021-01-13
CA2989975A1 (en) 2016-12-29
LT3313408T (lt) 2024-03-12
CA2989975C (en) 2021-10-12
NI201700173A (es) 2018-04-02
AU2016282863B2 (en) 2021-05-27
EA036497B1 (ru) 2020-11-17
BR112017028048A2 (pt) 2018-09-04
ZA201800067B (en) 2019-07-31
MX2017016801A (es) 2018-05-11
PH12017502379A1 (en) 2018-06-25
ES2970532T3 (es) 2024-05-29
CN108025014A (zh) 2018-05-11
SI3313408T1 (sl) 2024-04-30
SV2017005602A (es) 2018-08-14
KR102217942B1 (ko) 2021-02-19
JP2018527305A (ja) 2018-09-20
EA201792595A1 (ru) 2018-06-29
EP3313408B1 (en) 2023-12-06
SMT202400062T1 (it) 2024-03-13
CN113750108B (zh) 2025-08-19
NZ739195A (en) 2024-04-26
KR20180019173A (ko) 2018-02-23
DK3313408T3 (da) 2024-01-29
EP3313408A1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
MX2017016801A (es) Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
CL2020000747A1 (es) Formulaciones de niraparib.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112017028140A2 (pt) formulações farmacêuticas
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MY200278A (en) Methods of improving exercise capacity in fontan patients using udenafil compositions
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
ECSP19024033A (es) Composiciones de tesofensina
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
BR112017019364A2 (pt) dispersões sólidas
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
BR112018011483A2 (pt) métodos e composições farmacêuticas com estradiol vaginalmente inserido
UA120075C2 (uk) Фармацевтична композиція для лікування запальних змін прямої кишки
HRP20230105T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti
PH12019501607A1 (en) Tapentadol nasal composition
CL2012003685A1 (es) Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.
TH1701007675A (th) สารคุมกำเนิดที่มีดรอสไพรีโนนเป็นพื้นฐานสำหรับผู้ป่วยหญิงที่ประสบกับภาวะน้ำหนักมากเกิน